Clèries Soler, RamonAmeijide, AlbertoBuxó, MariaVilardell, MireiaMartínez, José MiguelFont, RebecaMarcos Gragera, RafaelPuigdemont, MontseViñas, GemmaCarulla, MariàEspinàs Piñol, Josep AlfonsGalceran, JaumeIzquierdo, ÁngelBorràs Andrés, Josep Maria2023-02-062023-02-062022-12-271660-4601https://hdl.handle.net/2445/193134Mortality from cardiovascular disease (CVD), second tumours, and other causes is of clinical interest in the long-term follow-up of breast cancer (BC) patients. Using a cohort of BC patients (N = 6758) from the cancer registries of Girona and Tarragona (north-eastern Spain), we studied the 10-year probabilities of death due to BC, other cancers, and CVD according to stage at diagnosis and hormone receptor (HR) status. Among the non-BC causes of death (N = 720), CVD (N = 218) surpassed other cancers (N = 196). The BC cohort presented a significantly higher risk of death due to endometrial and ovarian cancers than the general population. In Stage I, HR- patients showed a 1.72-fold higher probability of all-cause death and a 6.11-fold higher probability of breast cancer death than HR+ patients. In Stages II-III, the probability of CVD death (range 3.11% to 3.86%) surpassed that of other cancers (range 0.54% to 3.11%). In Stage IV patients, the probability of death from any cancer drove the mortality risk. Promoting screening and preventive measures in BC patients are warranted, since long-term control should encompass early detection of second neoplasms, ruling out the possibility of late recurrence. In patients diagnosed in Stages II-III at an older age, surveillance for preventing late cardiotoxicity is crucial.17 p.application/pdfengcc by (c) Clèries Soler, Ramon et al., 2022http://creativecommons.org/licenses/by/3.0/es/Càncer de mamaMalalties cardiovascularsMortalitatBreast cancerCardiovascular diseasesMortalityinfo:eu-repo/semantics/article2023-02-02info:eu-repo/semantics/openAccess